Impaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease

European Journal of Medical Research

Volumn 14, Issue 6, 2009, Pages 244-249

  Kastenbauer, U ^a   Wolf, E ^b   Kollan, C ^c   Hamouda, O ^c   Bogner, J R ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b MUC Research GmbH and MVZ Karlsplatz   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Antiretroviral therapy; CD4+ lymphocyte count; Highly active; HIV; Pneumocystis jiroveci pneumonia; Toxoplasmic encephalitis

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; ENCEPHALITIS; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; TOXOPLASMOSIS; VIRUS LOAD;

EID: 67651040101     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-14-6-244     Document Type: Article

References (31)

1. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001 Nov 15;33(10):1747-1755 (Pubitemid 33044543)
2. San-Andres FJ, Rubio R, Castilla J, Pulido F, Palao G, de P, I, et al. Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis 2003 May 1;36(9):1177-1185
3. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997 Nov 15;11(14):1731-1738 (Pubitemid 27470275)
4. Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther 2007;12(6):841-851 (Pubitemid 47492554)
5. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007 Nov 15;45(10):1369-1374
6. Pulvirenti J, Herrera P, Venkataraman P, Ahmed N. Pneumocystis carinii pneumonia in HIV-infected patients in the HAART era. AIDS Patient Care STDS 2003 Jun; 17(6):261-265 (Pubitemid 36791293)
7. Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. Webpage 2004Available from: URL: http://aidsinfo.nih.gov/contentfiles/ TreatmentofOI-AA.pdf
8. Clumeck N. Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe. Eur J Clin Microbiol Infect Dis 1991 Mar;10(3):177-178
9. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004 Jun 12;363(9425):1965-1976
10. Israelski DM, Chmiel JS, Poggensee L, Phair JP, Remington JS. Prevalence of Toxoplasma infection in a cohort of homosexual men at risk of AIDS and toxoplasmic encephalitis. J Acquir Immune Defic Syndr 1993 Apr;6(4):414-418 (Pubitemid 23112853)
11. Ancelle-Park R. Expanded European AIDS case definition. Lancet 1993 Feb 13;341(8842):441.
12. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992 Dec 18;41(RR-17):1-19.
13. Nath A, Sinai AP. Cerebral Toxoplasmosis. Curr Treat Options Neurol 2003 Jan;5(1):3-12.
14. Masters PA, O'Bryan TA, Zurlo J, Miller DQ, Joshi N. Trimethoprim- sulfamethoxazole revisited. Arch Intern Med 2003 Feb 24;163(4):402-410
15. Freund YR, Dabbs J, Creek MR, Phillips SJ, Tyson CA, MacGregor JT. Synergistic bone marrow toxicity of pyrimethamine and zidovudine in murine in vivo and in vitro models: mechanism of toxicity. Toxicol Appl Pharmacol 2002 May 15;181(1):16-26.
16. Kirk O, Reiss P, Uberti-Foppa C, Bickel M, Gerstoft J, Pradier C, et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002 Aug;%20;137(4):239-250 (Pubitemid 34898554)
17. + T-cell count < 200 cells/microl when viral replication is suppressed. AIDS 2007 Aug;%20;21(13):1711-1715
18. Linares GG, Gismondi S, Codesido NO, Moreno SN, Docampo R, Rodriguez JB. Fluorine-containing aryloxyethyl thiocyanate derivatives are potent inhibitors of Trypanosoma cruzi and Toxoplasma gondii proliferation. Bioorg Med Chem Lett 2007 Sep 15;17(18):5068-5071
19. el Kouni MH. Adenosine metabolism in Toxoplasma gondii: potential targets for chemotherapy. Curr Pharm Des 2007;13(6):581-597
20. Shubar HM, Mayer JP, Hopfenmuller W, Liesenfeld O. A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo. J Antimicrob Chemother 2008 Feb;%19;.
21. Moreno SN, Li ZH. Anti-infectives targeting the isoprenoid pathway of Toxoplasma gondii. Expert Opin Ther Targets 2008 Mar;12(3):253-263
22. Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, et al. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials). AIDS 2007 Sep 12;21(14):1887-1897.
23. Goldberg GL, Zakrzewski JL, Perales MA, van den Brink MR. Clinical strategies to enhance T cell reconstitution. Semin Immunol 2007 Oct 25;.
24. Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, et al. Discordant immunologic and virologie responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 2005 Nov 1;40(3):288-93. (Pubitemid 41533068)
25. Hafner R, Inderlied CB, Peterson DM, Wright DJ, Standiford HC, Drusano G, et al. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 1999 Aug;180(2):438-447 (Pubitemid 30256326)
26. Lazaro E, Coureau G, Guedj J, Blanco P, Pellegrin I, Commenges D, et al. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection. Antivir Ther 2006;11(3):343-350 (Pubitemid 43823553)
27. Kremer L, Estaquier J, Wolowczuk I, Biet F, Ameisen JC, Locht C. Ineffective cellular immune response associated with T-cell apoptosis in susceptible Mycobacterium bovis BCG-infected mice. Infect Immun 2000 Jul;68(7):4264-73.
28. Petakov M, Stojanovic N, Jovcic G, Bugarski D, Todorovic V, Djurkovic-Djakovic O. Hematopoiesis during acute Toxoplasma gondii infection in mice. Haematologia (Budap) 2002;32(4):439-455
29. Andrieu JM, Lu W, Levy R. Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J Infect Dis 1995 Mar;171(3):523-530
30. + T cell loss in therapy-naive HIV-patients without antiretroviral therapy. Eur J Med Res 2005 Mar 29;10(3):105-109 (Pubitemid 40514878)
31. Manzardo C, Zaccarelli M, Aguero F, Antinori A, Miro JM. Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. J Acquir Immune Defic Syndr 2007 Sep;46 Suppl 1:S9-18.:S9-18. (Pubitemid 47312321)